Abstract
Recent data from various experimental models support the link between extracellular tau and neurodegeneration; however, the exact mechanisms by which extracellular tau or its modified forms or aggregates cause neuronal death remain unclear. We have previously shown that exogenously applied monomers and oligomers of the longest tau isoform (2N4R) at micromolar concentrations induced microglial phagocytosis of stressed-but-viable neurons in vitro. In this study, we investigated whether extracellular phosphorylated tau2N4R (p-tau2N4R), isoform 1N4R (tau1N4R) and K18 peptide can induce neuronal death or loss in primary neuronal-glial cell cultures. We found that p-tau2N4R at 30 nM concentration induced loss of viable neurons; however, 700 nM p-tau2N4R caused necrosis of both neurons and microglia, and this neuronal death was partially glial cell-dependent. We also found that extracellular tau1N4R oligomers, but not monomers, at 3 μM concentration caused neuronal death in mixed cell cultures: self-assembly tau1N4R dimers-tetramers induced neuronal necrosis and apoptosis, whereas Aβ-promoted tau1N4R oligomers caused glial cell-dependent loss of neurons without signs of increased cell death. Monomeric and pre-aggregated tau peptide containing 4R repeats (K18) had no effect in mixed cultures, suggesting that tau neurotoxicity might be dependent on N-terminal part of the protein. Taken together, our results show that extracellular p-tau2N4R is the most toxic form among investigated tau species inducing loss of neurons at low nanomolar concentrations and that neurotoxicity of tau1N4R is dependent on its aggregation state.
This is a preview of subscription content, access via your institution.




Availability of Data and Materials
The data that support the findings of this study are available from the corresponding author upon request.
Abbreviations
- Aβ:
-
Amyloid-β
- Aβ1–42 :
-
Amyloid-β 1 to 42 amino acid peptide
- AD:
-
Alzheimer’s disease
- Ara-C:
-
Cytosine β- D–arabinofuranoside
- BSA:
-
Bovine serum albumin
- CGC:
-
Cerebellar granule cells
- CSF:
-
Cerebrospinal fluid
- DIV:
-
Days in vitro
- DMEM:
-
Dulbecco’s Modified Eagle Medium
- GSK-3β:
-
Glycogen synthase kinase-3β
- HEPES:
-
(4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid)
- EDTA:
-
Ethylenediaminetetraacetic acid
- ERK:
-
Extracellular signal-regulated kinases
- ISF:
-
Interstitial fluid
- MAPT:
-
Microtubule-associated protein tau
- MAPK:
-
Mitogen-activated protein kinases
- NMDA:
-
N-methyl-D-aspartate
- NFT:
-
Neurofibrillary tangles
- PHF:
-
Paired helical filaments
- PI:
-
Propidium iodide
- PVDF:
-
Polyvinylidene fluoride
- tau:
-
Tubulin associated unit
- tau1N4R :
-
Recombinant full-length tau 1N4R
- tau2N4R :
-
Recombinant full-length tau 2N4R
- p-tau:
-
Phosphorylated tau
- p-tau2N4R :
-
GSK-3β-phosphorylated recombinant full-length tau 2N4R
- SDS:
-
Sodium dodecyl sulfate
- SDS-PAGE:
-
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
- LDS:
-
Lithium dodecyl sulfate
References
Iqbal K, Liu F, Gong C-X, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7:656–664. https://doi.org/10.2174/156720510793611592
Laurent C, Buée L, Blum D (2018) Tau and neuroinflammation: what impact for Alzheimer’s disease and tauopathies? Biom J 41:21–33
Chong FP, Ng KY, Koh RY, Chye SM (2018) Tau proteins and tauopathies in Alzheimer’s disease. Cell Mol Neurobiol 38:965–980
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404. https://doi.org/10.1007/s00401-006-0127-z
Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W (2019) Biomarkers for tau pathology. Mol Cell Neurosci 97:18–33. https://doi.org/10.1016/J.MCN.2018.12.001
Yang CC, Chiu MJ, Chen TF, Chang HL, Liu BH, Yang SY (2018) Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer’s disease. J Alzheimers Dis 61:1323–1332. https://doi.org/10.3233/JAD-170810
Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 129:3035–3041. https://doi.org/10.1093/brain/awl269
Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF (2010) Interneuronal transfer of human tau between lamprey central neurons in situ. J Alzheimers Dis 19:647–664. https://doi.org/10.3233/JAD-2010-1273
Pernègre C, Duquette A, Leclerc N (2019) Tau secretion: good and bad for neurons. Front Neurosci 13:649. https://doi.org/10.3389/fnins.2019.00649
Thomann PA, Kaiser E, Schönknecht P, Pantel J, Essig M, Schröder J (2009) Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci 34:136–142
Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, Wang J (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160:1269–1278. https://doi.org/10.1016/S0002-9440(10)62554-0
Jankeviciute S, Psemeneckiene G, Morkuniene R et al (2019) Cerebrospinal fluids from Alzheimer’s disease patients exhibit neurotoxic effects on neuronal cell cultures. Eur J Neurosci EJN:14389. https://doi.org/10.1111/ejn.14389
Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804. https://doi.org/10.1056/NEJMoa1202753
Llorens F, Villar-Piqué A, Candelise N et al (2019) Tau protein as a biological fluid biomarker in neurodegenerative dementias. In: Cognitive Disorders. IntechOpen. https://doi.org/10.5772/intechopen.73528
Takeda S, Commins C, DeVos SL et al (2016) Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer’s disease mouse model and human patients. Ann Neurol 80:355–367. https://doi.org/10.1002/ana.24716
Meredith JE, Sankaranarayanan S, Guss V et al (2013) Characterization of novel CSF tau and ptau biomarkers for Alzheimer’s disease. PLoS One 8:e76523. https://doi.org/10.1371/journal.pone.0076523
Barthélemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L et al (2016) Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with lewy bodies. J Alzheimers Dis 51:1033–1043. https://doi.org/10.3233/JAD-150962
Zemlan F, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA et al (1999) Quantification of axonal damage in traumatic brain injury. J Neurochem 72:741–750. https://doi.org/10.1046/j.1471-4159.1999.0720741.x
Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R et al (2012) Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 123:396–405. https://doi.org/10.1111/j.1471-4159.2012.07911.x
Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, Usami M, Shoji M et al (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 186:181–183. https://doi.org/10.1016/0304-3940(95)11291-4
Russell CL, Mitra V, Hansson K, Blennow K, Gobom J, Zetterberg H, Hiltunen M, Ward M et al (2016) Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates. J Alzheimers Dis 55:303–313. https://doi.org/10.3233/JAD-160633
Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, Mandelkow EM, Mandelkow E et al (2017) What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun 5:99
Plouffe V, Mohamed N-V, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N (2012) Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS One 7:e36873. https://doi.org/10.1371/journal.pone.0036873
Wauters M, Wattiez R, Ris L (2016) Internalization of the extracellular full-length tau inside Neuro2A and cortical cells is enhanced by phosphorylation. Biomolecules 6:36. https://doi.org/10.3390/biom6030036
Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I et al (2016) Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep 6:19393. https://doi.org/10.1038/srep19393
Swanson E, Breckenridge L, McMahon L, Som S, McConnell I, Bloom GS (2017) Extracellular tau oligomers induce invasion of endogenous tau into the somatodendritic compartment and axonal transport dysfunction. J Alzheimers Dis 58:803–820. https://doi.org/10.3233/JAD-170168
Evans LD, Wassmer T, Fraser G, Smith J, Perkinton M, Billinton A, Livesey FJ (2018) Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep 22:3612–3624. https://doi.org/10.1016/j.celrep.2018.03.021
Michel CH, Kumar S, Pinotsi D, Tunnacliffe A, St. George-Hyslop P, Mandelkow E, Mandelkow EM, Kaminski CF et al (2014) Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J Biol Chem 289:956–967. https://doi.org/10.1074/jbc.M113.515445
Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N (2019) Neuroinflammation as a common feature of neurodegenerative disorders. Front Pharmacol 10:1008. https://doi.org/10.3389/fphar.2019.01008
Bolós M, Llorens-Martín M, Jurado-Arjona J, Hernández F, Rábano A, Avila J (2015) Direct evidence of internalization of tau by microglia in vitro and in vivo. J Alzheimers Dis 50:77–87. https://doi.org/10.3233/JAD-150704
Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O et al (2015) Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18:1584–1593. https://doi.org/10.1038/nn.4132
Guix FX, Corbett GT, Cha DJ et al (2018) Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci 19(3):E663. https://doi.org/10.3390/ijms19030663
Hopp SC, Lin Y, Oakley D, Roe AD, DeVos SL, Hanlon D, Hyman BT (2018) The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer’s disease. J Neuroinflammation 15(1):269. https://doi.org/10.1186/s12974-018-1309-z
Kovac A, Zilka N, Kazmerova Z, Cente M, Zilkova M, Novak M (2011) Misfolded truncated protein τ induces innate immune response via MAPK pathway. J Immunol 187:2732–2739. https://doi.org/10.4049/jimmunol.1100216
Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granérus AK, Vanderstichele H et al (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 70:624–630. https://doi.org/10.1136/jnnp.70.5.624
Hassan-Abdi R, Brenet A, Bennis M, Yanicostas C, Soussi-Yanicostas N (2019) Neurons expressing pathological tau protein trigger dramatic changes in microglial morphology and dynamics. Front Neurosci 13:1199. https://doi.org/10.3389/fnins.2019.01199
Pampuscenko K, Morkuniene R, Sneideris T, Smirnovas V, Budvytyte R, Valincius G, Brown GC, Borutaite V (2019) Extracellular tau induces microglial phagocytosis of living neurons in cell cultures. J Neurochem 154:316–329. https://doi.org/10.1111/jnc.14940
Brelstaff J, Tolkovsky AM, Ghetti B et al (2018) Living neurons with tau filaments aberrantly expose phosphatidylserine and are phagocytosed by microglia. Cell Rep 24:1939–1948.e4. https://doi.org/10.1016/j.celrep.2018.07.072
Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9:4225–4230
Bal-Price A, Brown GC (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21:6480–6491
Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ et al (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49:10039–10041. https://doi.org/10.1021/bi1016233
Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Broccio M, Lösche M, Niaura G, Valincius G et al (2010) Size-dependent neurotoxicity of β-amyloid oligomers. Arch Biochem Biophys 496:84–92. https://doi.org/10.1016/j.abb.2010.02.001
Sanchez-Mejias E, Navarro V, Jimenez S, Sanchez-Mico M, Sanchez-Varo R, Nuñez-Diaz C, Trujillo-Estrada L, Davila JC et al (2016) Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration. Acta Neuropathol 132:897–916. https://doi.org/10.1007/s00401-016-1630-5
Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK et al (2014) Neuronal activity regulates extracellular tau in vivo. J Exp Med 211:387–393. https://doi.org/10.1084/jem.20131685
Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM et al (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31:13110–13117. https://doi.org/10.1523/JNEUROSCI.2569-11.2011
Reynolds MR, Berry RW, Binder LI (2005) Site-specific nitration differentially influences τ assembly in vitro. Biochemistry 44:13997–14009. https://doi.org/10.1021/bi051028w
Gamblin TC, Berry RW, Binder LI (2003) Modeling tau polymerization in vitro: a review and synthesis. Biochemistry 42:15009–15017. https://doi.org/10.1021/bi035722s
Avila J (2010) Intracellular and extracellular tau. Front Neurosci 4:49. https://doi.org/10.3389/fnins.2010.00049
Khatoon S, Grundke-Iqbal I, Iqbal K (1994) Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett 351:80–84. https://doi.org/10.1016/0014-5793(94)00829-9
Espíndola SL, Damianich A, Alvarez RJ, Sartor M, Belforte JE, Ferrario JE, Gallo JM, Avale ME (2018) Modulation of tau isoforms imbalance precludes tau pathology and cognitive decline in a mouse model of Tauopathy. Cell Rep 23:709–715. https://doi.org/10.1016/j.celrep.2018.03.079
Espinoza M, de Silva R, Dickson DW, Davies P (2008) Differential incorporation of tau isoforms in Alzheimer’s disease. J Alzheimers Dis 14:1–16. https://doi.org/10.3233/JAD-2008-14101
Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, Beach T, Rogers J et al (2001) Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 101:167–173. https://doi.org/10.1007/s004010000283
de Silva R, Lashley T, Strand C, Shiarli AM, Shi J, Tian J, Bailey KL, Davies P et al (2006) An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol 111:329–340. https://doi.org/10.1007/s00401-006-0048-x
Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M et al (2013) Small Misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288:1856–1870. https://doi.org/10.1074/jbc.M112.394528
Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol 2013:1–9. https://doi.org/10.1155/2013/260787
Usenovic M, Niroomand S, Drolet RE, Yao L, Gaspar RC, Hatcher NG, Schachter J, Renger JJ et al (2015) Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J Neurosci 35:14234–14250. https://doi.org/10.1523/JNEUROSCI.1523-15.2015
Lasagna-Reeves CA, Sengupta U, Castillo-Carranza D, Gerson JE, Guerrero-Munoz M, Troncoso JC, Jackson GR, Kayed R (2014) The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun 2:56. https://doi.org/10.1186/2051-5960-2-56
Morales I, Jiménez JM, Mancilla M, Maccioni RB (2013) Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis 37:849–856. https://doi.org/10.3233/JAD-131843
Perea JR, Ávila J, Bolós M (2018) Dephosphorylated rather than hyperphosphorylated tau triggers a pro-inflammatory profile in microglia through the p38 MAPK pathway. Exp Neurol 310:14–21. https://doi.org/10.1016/j.expneurol.2018.08.007
Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H, Westaway D, George-Hyslop PS et al (2008) Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L. Brain Res 1214:159–168. https://doi.org/10.1016/j.brainres.2008.02.084
Atlante A, Amadoro G, Bobba A, de Bari L, Corsetti V, Pappalardo G, Marra E, Calissano P et al (2008) A peptide containing residues 26–44 of tau protein impairs mitochondrial oxidative phosphorylation acting at the level of the adenine nucleotide translocator. Biochim Biophys Acta Bioenerg 1777:1289–1300. https://doi.org/10.1016/j.bbabio.2008.07.004
Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N (2006) NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A 103:2892–2897. https://doi.org/10.1073/pnas.0511065103
Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, Hansson O, Parnetti L et al (2019) Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. Acta Neuropathol 137:279–296. https://doi.org/10.1007/s00401-018-1948-2
Funding
This work was supported by the Research Council of Lithuania, Bilateral Exchange Project Joint Research grant S-LJB-18-2 INFLAMTAU.
Author information
Authors and Affiliations
Contributions
KP carried out experiments on cell cultures, analysed and wrote the manuscript. LK and VS performed expression and purification of recombinant tau protein. RM planned the experiments, analysed data and wrote the manuscript. TT analysed data and wrote the manuscript. VB initiated, planned and supervised the study, wrote the manuscript. All authors reviewed the final manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
Authors declare that they have no conflict of interest.
Ethics Approval
Approved by Lithuanian State Food and Veterinary Service, ethical approval No. B6(1.9)-855.
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Code Availability (Software Application or Custom Code)
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pampuscenko, K., Morkuniene, R., Krasauskas, L. et al. Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures. Mol Neurobiol 58, 658–667 (2021). https://doi.org/10.1007/s12035-020-02150-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-020-02150-7